Africa CDC blames lack of international interest for Bundibugyo Ebola vaccine gap
Director-General Jean Kaseya says the Bundibugyo strain lacks an approved vaccine because partners viewed it as an African issue.
The Director-General of the Africa Centres for Disease Control and Prevention, Dr Jean Kaseya, has blamed a lack of international interest in the Bundibugyo strain of Ebola for the absence of an approved vaccine. He stated that if the outbreak were in Western countries, a vaccine would already be available. Kaseya said some partners decided to consider the issue as an African issue and were not interested.
The Bundibugyo strain has received less attention partly because it has caused fewer outbreaks than the Zaire strain, which has been responsible for more than 16 outbreaks. Nigeria confirmed its first imported case of Bundibugyo Ebola in the Federal Capital Territory on October 20, involving a woman who recently travelled from Uganda. Health authorities identified 44 contacts for monitoring.
To address the gap, the Africa CDC is initiating clinical trials of new vaccine candidates. An African manufacturer in Egypt is currently conducting clinical trials of a potential vaccine against the Bundibugyo strain. The agency is also working with Uganda and the Democratic Republic of the Congo to make the Zaire strain vaccine, Ervebo, available for compassionate use and clinical trials.
Kaseya said the response is part of an effort to prevent Africa from being left behind in the production of medicines, diagnostic tools, and vaccines. He noted that 28 African countries, representing more than 50 per cent of the continent, have contributed funds to support the response.
The current outbreak should lead to lasting changes in how Africa prepares for public health emergencies. These changes include better coordination among international partners, increased domestic funding, and increased local vaccine manufacturing.
Key facts
- The Bundibugyo Ebola strain lacks an approved vaccine due to a lack of international interest.
- Nigeria confirmed an imported case of Bundibugyo Ebola in the Federal Capital Territory on October 20.
- An African manufacturer in Egypt is conducting clinical trials for a potential Bundibugyo vaccine.
- Twenty-eight African countries have provided funding for the outbreak response.
Three perspectives
Neutral
The Africa CDC is working with Uganda and the Democratic Republic of the Congo to make the Ervebo vaccine available for clinical trials and compassionate use.
Positive
Twenty-eight African countries have contributed funds to support the response, which Kaseya described as a sign of changing attitudes towards financing the continent's health emergencies.
Negative
The Bundibugyo strain lacks an approved vaccine because international partners viewed the issue as an African issue and showed a lack of interest.
Your week in news, every Wednesday
The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.